- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:26 | VC firm Hatteras reels in $200M across 2 funds for early-stage life sciences investments | ||
| 15:26 | Response's ex-Sanofi asset hits midphase goal in post-GLP-1 patients | ||
| 12:26 | Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs | ||
| 12:26 | Generation jettisons 90% of employees due to lack of time, cash to develop autoimmune tech | ||
| Di | NIH director says public distrust prompted federal mRNA vaccine development discontinuation | ||
| Di | Biohaven trashes troriluzole in OCD after asset bungles phase 3 trial | ||
| Di | ARPA-H data chief departs over disagreement with mRNA vaccine rollback | ||
| Di | PureTech launches Celea Therapeutics to develop highly touted lung disease candidate | ||
| Di | Bayer picks Kumquat for KRAS collaboration, with $1.3B on offer if pact bears fruit | ||
| Di | Novartis' blood disorder readout earns Novartis 3rd phase 3 win for ianalumab this week | ||
| Di | Vaxart seeks answers as BARDA funding for stop-start vaccine project dries up again | ||
| Mo | Novel RNA biotech winds down after missing milestone in Bayer pact | ||
| Mo | Expedition inks $645M pact to pocket Fosun's lung disease asset in knapsack | ||
| Mo | Cancer vaccine's 'narrow' phase 3 fail won't stop IO heading to FDA | ||
| Mo | Novartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed | ||
| Fr | Stealth Bio questions its own viability as FDA directs rare disease biotech to resubmit drug application | ||
| Fr | Gilead culls Novo-partnered MASH candidate and 2 cancer assets | ||
| Fr | Bicycle lays off 25% of workforce as Genentech rides away from R&D pact | ||
| Do | Strand's Big Pharma-backed series B brings in $153M to advance mRNA tumor drugs | ||
| Do | Eli Lilly shakes up pain pipeline as part of quarterly R&D clearout | ||
| Do | Minghui raises $131M 'pre-IPO' round to bankroll JAK inhibitor launch, ADC trials | ||
| Do | Gilead hands back one Arcus cancer candidate from $725M deal | ||
| Do | Keros shakes up leadership structure to go all in on DMD drug | ||
| 06.08. | NIH broke law by withholding Congress-approved funding: GAO | ||
| 06.08. | Flagship Pioneering's Alltrna sheds staff as it readies for clinical debut |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .